Hey @stockrock,
Great find thanks for posting the interview, this Company is heading in the right direction, just wished my father who pasted away with pancreatic cancer a couple of years back had the opportunity to trial Chimeric treatments had they been better known – taking into account just officially listed in Jan this year. I was unaware of them and been following Mesoblast, Imugene and Bitron all with skin in the game and now M that also looks excellent.
I guess my question is with both Leslie & Paul being Directors in both and Paul founding them why not merge, are their synergies that different ? IMU into oncolytic therapies’ and CHM in cell therapy specifically in the CAR-T space, to a layman like myself it just makes good sense.
Cheers,
ST
Hey @stockrock, Great find thanks for posting the interview,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.76K | 2.928M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 4817793 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18563373 | 21 |
View Market Depth
| Last trade - 14.13pm 26/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |